Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Cognition in Schizophrenia
Interventions
DRUG

Mecamylamine

A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.

DRUG

Varenicline

A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.

DRUG

Placebo

The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.

Trial Locations (1)

02114

Freedom Trail Clinic, Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

collaborator

The Bowman Family Foundation

UNKNOWN

lead

Massachusetts General Hospital

OTHER

NCT00455650 - Study of the Effects of Mecamylamine and Varenicline in Schizophrenia | Biotech Hunter | Biotech Hunter